Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,263.22 -14.29 (-0.27%) Dow
38,417.37 -268.95 (-0.70%) Nasdaq
16,761.25 +26.23 (+0.16%) Bitcoin USD
69,411.35 +1,268.84 (+1.86%) CMC Crypto 200
1,489.72 +21.79 (+1.49%)
BHVN Dec 2025 45.000 put
| Previous close | 17.50 |
| Open | N/A |
| Bid | 15.50 |
| Ask | 19.70 |
| Strike | 45.00 |
| Expiry date | 2025-12-19 |
| Day's range | 17.50 - 17.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
GuruFocus.comDirector Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 15,000 shares of the company.
